Results 101 to 110 of about 6,979 (257)
Frontiers in Pharmacology, 2018 The antidiabetic biguanide metformin exerts antiproliferative effects in different solid tumors. However, during preclinical studies, metformin concentrations required to induce cell growth arrest were invariably within the mM range, thus difficult to ...
Federica Barbieri +13 more
doaj +1 more source
The strange case of AMPK and cancer:Dr Jekyll or Mr Hyde? [PDF]
, 2019 The AMP-activated protein kinase (AMPK) acts as a cellular energy sensor. Once switched on by increases in cellular AMP : ATP ratios, it acts to restore energy homeostasis by switching on catabolic pathways while switching off cell growth and ...
Barnes K +7 more
core +2 more sources
Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications [PDF]
, 2019 Background: Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease (GD). Diabetes mellitus (DM) has been reported to be a risk factor in patients with GO.
Biondi, B +5 more
core +2 more sources
Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics
Cell Reports, 2016 Epithelial malignancies are effectively treated by antiangiogenics; however, acquired resistance is a major problem in cancer therapeutics. Epithelial tumors commonly have mutations in the MAPK/Pi3K-AKT pathways, which leads to high-rate aerobic ...
Paloma Navarro +11 more
doaj +1 more source
Syrosingopine sensitizes cancer cells to killing by metformin [PDF]
, 2016 We report that the anticancer activity of the widely used diabetic drug metformin is strongly potentiated by syrosingopine. Synthetic lethality elicited by combining the two drugs is synergistic and specific to transformed cells. This effect is unrelated
Benjamin, Don +13 more
core +1 more source
lncRNA NBR2 modulates cancer cell sensitivity to phenformin through GLUT1 [PDF]
, 2016 Xiaowen Liu, Boyi Gan
openalex +1 more source